குழந்தைகள் மருத்துவமனை இல் வாண்டர்பில்ட் பல்கலைக்கழகம் மருத்துவ மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

 E-Mail ATS 2021, New York, NY - Results from the VOYAGE study of dupilumab (Dupixent) showed that the monoclonal antibody significantly reduced exacerbations in children ages 6-11 with uncontrolled moderate-to-severe asthma, compared to placebo, according to research presented at the ATS 2021 International Conference. VOYAGE (NCT02948959) is a recently completed randomized, placebo-controlled double-blind multicenter phase 3 clinical trial, that took place in a number of countries. Dupilumab also rapidly improved lung function within two weeks, an improvement that was sustained for up to 52 weeks (the length of the trial), compared to placebo. We hope results from the VOYAGE trial will lay the groundwork for dupilumab as a potential new treatment option for patients aged 6 to 11 with moderate-to-severe asthma, said study author/investigator Leonard B. Bacharier, MD, professor of pediatrics, allergy/immunology/pulmonary medicine, Monroe Carell Jr. Children s Hospital at Vande

New yorkUnited statesMonroe carell jrLeonardb bacharierRegeneron pharmaceuticals incInternational conferenceChildren hospital at vanderbilt university medical centerMonroe carellVanderbilt university medicalRegeneron pharmaceuticalsMedicine healthImmunology allergies asthmaPulmonary respiratory medicineபுதியது யார்க்ஒன்றுபட்டது மாநிலங்களில்மன்ரோ கவனிப்பு ஜூனியர்